Tech Company M&A Transactions
SARCode Bioscience Acquisition
On 3/26/2013, SARCode Bioscience was purchased by Shire Pharmaceuticals. Financial terms set the valuation at $160 million.
Transaction Overview
Company Name
Acquired By
Announced On
3/26/2013
Transaction Type
M&A
Amount
$160,000,000
M&A Terms
In addition to the upfront payment of $160 million, shareholders in California-based SARcode will be eligible for additional undisclosed payments upon achievement of certain drug development and commercial milestones.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
1000 Marina Boulevard 250
Brisbane, CA 94005
USA
Brisbane, CA 94005
USA
Phone
Website
Email Address
Overview
SARcode is a private company focused on the development of small molecule LFA-1 inhibitors to treat inflammatory diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Quinton Oswald
Chief Financial Officer
Todd Creech
Chief Medical Officer
Charles Semba
VP - Manufacturing
Lane Welton
VP - Regulatory Affairs
Mary Newman
Browse more venture capital transactions:
Prev: 3/26/2013: BA Insight venture capital transaction
Next: 3/26/2013: Edge Therapeutics venture capital transaction
Share this article
News on VC Transactions
We do our best to report on tech company VC transactions. VC transactions on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs